Elosulfase alfa 24 month-like review

This 24 month-like review aimed to ensure that the listing of elosulfase alfa for the treatment of MPS IVA on the LSDP remains appropriate. It was considered by the Expert Panel at its October 2022 and February 2023 meetings.

Help us improve health.gov.au

If you would like a response please provide an email address. Your email address is covered by our privacy policy.